Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Hep C treatment peginterferon reduces the virus but liver damage continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

5 Dec 2008

Interferon as long-term treatment for hepatitis C not effective

Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.

5 Dec 2008

Low-dose peginterferon used for hepatitis C doesn't work

An NIH funded multi-center clinical trial found no benefit from "maintenance therapy," low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment.

3 Dec 2008

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor.

1 Dec 2008

Liver disease tackled with dedicated unit at Imperial College London

Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.

1 Dec 2008

Declines in cancer incidence and death rates across U.S.

A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in some of the most common types of cancer.

25 Nov 2008

Discovery of 13 new tumor-suppressor genes in liver cancer

Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.

18 Nov 2008

Celprogen introduces in vivo model for human glioblastoma

Celprogen Inc. has announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma.

18 Nov 2008

Liver transplant recipients face increased risks of developing cancer

A new Canadian study comparing cancer rates of liver transplant patients to those of the general population has found that transplant recipients face increased risks of developing cancer, especially non-Hodgkin's lymphoma and colorectal cancer.

4 Nov 2008

By imaging live cells, researchers show how hepatitis C replicates

The hepatitis C virus is a prolific replicator, able to produce up to a trillion particles per day in an infected person by hijacking liver cells in which to build up its viral replication machinery.

30 Oct 2008

Phenomix starts phase 1a trial of hepatitis C protease inhibitor

Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

28 Oct 2008

Chance of dying from cancer before the age of 84 is falling

The chance of dying from cancer before the age of 84 is becoming much smaller for most types of cancer and should continue falling over the next 20 years according to a new study from Cancer Research UK.

19 Oct 2008

Gene variant boosts risk of fatty liver disease

Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation.

25 Sep 2008

CDC recommends Asian, African immigrants be tested for hepatitis B

According to new guidelines CDC officials made public on Thursday, people born in either Asia or Africa who currently live in the U.S. should be tested for hepatitis B, the San Francisco Chronicle reports.

22 Sep 2008

Lung cancer in non-smokers is sixth biggest cancer killer

While lung cancer in smokers and former smokers is the biggest cancer killer by far, lung cancer in people who have never smoked is -- by itself -- the sixth biggest cancer killer in the United States.

15 Sep 2008

Health care professionals seeing more children with fatty liver disease; condition prevalent among Hispanics

As many as 2% to 5% of children older than age five -- most of whom are obese -- are thought to have nonalcoholic fatty liver disease, and the condition seems to be most prevalent among Hispanic children, the AP/San Mateo Daily Journal reports.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Protherics announces start of Prolarix phase 2 study in liver cancer

Protherics PLC today announced the initiation of a phase 2a proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treaent of primary liver cancer (hepatocellular carcinoma or "HCC"). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.

27 Aug 2008

Hunt for baby denied HBV shot

Authorities in New South Wales, Australia, continue to search for a couple who have refused to have their newborn baby immunised against hepatitis B.

25 Aug 2008

FDA approves Gilead's antiretroviral Viread for hepatitis B

Gilead Sciences on Monday announced that it has received FDA approval to market its antiretroviral drug Viread as a hepatitis B treatment, the AP/International Herald Tribune reports (AP/International Herald Tribune, 8/12).

13 Aug 2008